A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

International Journal of Cancer

Volumn 92, Issue 5, 2001, Pages 738-747

  Cassinelli, Giuliana ^a   Supino, Rosanna ^a   Perego, Paola ^a   Polizzi, Donatella ^a   Lanzi, Cinzia ^a   Pratesi, Graziella ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cell cycle checkpoint; Cell death; Ovarian carcinoma; P53; Taxanes

Indexed keywords

CISPLATIN; MUTANT PROTEIN; ORTATAXEL; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN P53; TAXANE DERIVATIVE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXICITY; DEPHOSPHORYLATION; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OSTEOSARCOMA CELL; OVARY CARCINOMA; PRIORITY JOURNAL; SENSITIZATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRIDGED COMPOUNDS; CELL CYCLE; DNA, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TUBULIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035371646     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2     Document Type: Article

References (40)

1. Paclitaxel pharmacology and other tumor types
2. Molecular effects of paclitaxel: Myths and reality (a critical review)
3. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel
4. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis
5. p53-independent apoptosis induced by paclitaxel through an indirect mechanism
6. Molecular mechanisms of resistance to taxanes. Implications for improvement of therapy
7. p53 in drug resistance in ovarian cancer
8. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
9. Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to paclitaxel
10. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection
11. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts
12. 14Beta-hydroxy-10-deacetyl-baccatin III, a new taxane from Himalayan yew (Taxus wallichiana Zucc.)
13. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells
14. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents
15. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: Hypersensitivity of p53-mutant human tumour xenografts
16. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia, 2nd edition
17. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
18. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
19. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
20. Mechanisms of taxol-induced cell death are concentration dependent
21. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis
22. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest
23. Bcl-2 is the guardian of microtubule integrity
24. cdc2 coincident with paclitaxel-induced apoptosis
25. WAF1 and p53 requires c-raf-1
26. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption
27. Cell death beyond apoptosis
28. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
29. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro
30. cdc2 and apoptosis
31. cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells
32. Up-regulation of CDC2 protein during paclitaxel-induced apoptosis
33. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol
34. Negative regulation of Weel expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis
35. Loss of normal p53 function confers sensitization to paclitaxel by increasing G2/M arrest and apoptosis
36. Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity
37. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control
38. 1-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression
39. 1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis
40. The biology of ovarian cancer